SCHEMBL1542335

SCHEMBL1542335

COc1c(CBr)cc(Br)cc1C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.38
DHFR P00374 1/20 0.35
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
HTR2A P28223 1/20 0.33
CA2 P00918 3/20 0.32
CA1 P00915 2/20 0.32
PTGS1 P23219 1/20 0.32
HSD17B10 Q99714 1/20 0.32
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
CYP3A4 P08684 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
CA4 P22748 2/20 0.31
TNFRSF1A P19438 2/20 0.31
EGFR P00533 1/20 0.30
ERBB2 P04626 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1304740 0.82 PTGS2 (0.50) PTGS2DHFRALDH1A1TSHRTDP1
SCHEMBL14211626 0.82 HSD17B10 (0.38) TDP1CA2CA1HSD17B10LMNA
SCHEMBL1530698 0.77 HSD17B10 (0.47) PTGS2ALDH1A1TSHRTDP1PTGDR2
SCHEMBL11222378 0.77 HSD17B10 (0.47) ALDH1A1TSHRHTR2ACA2CA1
SCHEMBL7968046 0.76 PTGS2 (0.41) PTGS2DHFRALDH1A1TSHRTDP1
SCHEMBL14112766 0.76 ALOX15 (0.44) PTGS2ALDH1A1TSHRTDP1PTGDR2
SCHEMBL3602794 0.76 KDM4E (0.38) ALDH1A1CA2CA1HSD17B10LMNA
SCHEMBL3212159 0.76 ALOX15 (0.44) PTGS2TDP1CA2CA1CYP3A4
SCHEMBL12678876 0.74 PTGS2 (0.40) PTGS2DHFRALDH1A1TSHRTDP1
SCHEMBL1730807 0.74 PTGS2 (0.40) PTGS2DHFRALDH1A1TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP disclosed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B PTGS2 3032/4885DHFR 732/4885ALDH1A1 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.